Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Fineline Cube Jul 2, 2026
Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Fineline Cube Jul 2, 2026
Policy / Regulatory

China Launches Major Public Health Initiatives to Enhance Healthcare Accessibility

Fineline Cube Feb 14, 2025

In a bid to bolster public health infrastructure and improve healthcare services, China’s National Health...

Company Drug

Sanofi and J&J’s E. coli Vaccine Fails Phase III Study

Fineline Cube Feb 14, 2025

France-based Sanofi (NASDAQ: SNY) and US giant Johnson & Johnson’s (J&J, NYSE: JNJ) vaccine candidate...

Company Drug

Antengene’s Xpovio Included in Taiwan’s NHI Drug List for Myeloma Treatment

Fineline Cube Feb 14, 2025

China-based biopharma Antengene Corp., Ltd (HKG: 6996) announced that its Xpovio (selinexor), the world’s first...

Company Deals

Boehringer Ingelheim Partners with ExpressionEdits on Gene Therapy Tech

Fineline Cube Feb 14, 2025

German pharmaceutical giant Boehringer Ingelheim has entered into a collaboration and licensing agreement with UK-based...

Company Drug

Merck’s Zerbaxa Approved by China’s NMPA for Complex Infections

Fineline Cube Feb 14, 2025

US-based pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) announced that it has...

Policy / Regulatory

Hainan Unveils Biomedical New Technology Policy to Boost Medical Innovation

Fineline Cube Feb 13, 2025

In-Depth Analysis and Orientation Guide for Hainan’s Biomedical New Technology PolicyThe Hainan Provincial Health Commission,...

Company Drug

Roche’s Evrysdi Tablet Approved by FDA for Spinal Muscular Atrophy

Fineline Cube Feb 13, 2025

Swiss giant Roche (SWX: ROG) has announced that it has received marketing approval from the...

Policy / Regulatory

Shanghai’s Ambitious Plan to Revolutionize Brain-Computer Interfaces

Fineline Cube Feb 13, 2025

In-Depth Analysis and Orientation Guide for Shanghai’s Brain-Computer Interface (BCI) PolicyShanghai has unveiled a groundbreaking...

Company Drug

Pfizer’s Adcetris Gets New FDA Approval for Lymphoma Treatment

Fineline Cube Feb 13, 2025

US giant Pfizer (NYSE: PFE) has announced that it has received another indication approval from...

Company Deals

StairMed Raises Record RMB350m for Implantable BCI Development

Fineline Cube Feb 13, 2025

Shanghai StairMed Technology Co., Ltd., a specialist in implantable brain-computer interface (BCI) technology, has reportedly...

Company Drug

Lundbeck’s Amlenetug Receives FDA Fast Track for Multiple System Atrophy

Fineline Cube Feb 13, 2025

Denmark-based pharma company Lundbeck A/S (VIE: LUNB) has announced that it has received Fast Track...

Company Drug

OnCusp Therapeutics’ CUSP06 Receives FDA Fast Track for Ovarian Cancer

Fineline Cube Feb 13, 2025

Sino-US company OnCusp Therapeutics Inc. has announced that it has received Fast Track Designation (FTD)...

Company Deals

J&J Considers Selling Stroke Care Business Cerenovus for USD1-1.5 Billion

Fineline Cube Feb 13, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) is reportedly considering selling its stroke care...

Company Deals

Anhui Anke to Invest in Visen Pharma’s Hong Kong IPO as Cornerstone Investor

Fineline Cube Feb 13, 2025

China – based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) has announced its plan...

Company Drug

Boao Airport Customs Releases First Batch of Modulen IBD for Crohn’s Disease Management

Fineline Cube Feb 13, 2025

The Boao Airport Customs under Haikou Customs has released the first batch of 96 pieces...

Company Deals

AbbVie Collaborates with Xilio Therapeutics on Tumor-Activated Immunotherapies

Fineline Cube Feb 13, 2025

US pharmaceutical giant AbbVie (NYSE: ABBV) has announced a collaboration and option-to-license agreement with fellow...

Company Drug

Astellas Pharma’s Izervay Gets FDA Approval for GA Treatment Without Dosing Limit

Fineline Cube Feb 13, 2025

Japan-based Astellas Pharma Inc. (TYO: 4503) has announced that the US Food and Drug Administration...

Company Deals

Andon Health to Fully Control iHealth by Acquiring Best Ventures’ Stake

Fineline Cube Feb 13, 2025

China-based Andon Health Co., Ltd (SHE: 002432) announced a plan to obtain the 20% stake...

Company

Hengrui Pharma’s BD Head Dr. Chen Dong Departs for AbbVie’s External Innovation Role

Fineline Cube Feb 13, 2025

Dr. Chen Dong, Vice President and China Head of BD at Jiangsu Hengrui Pharmaceuticals Co.,...

Company Drug

Huadong Medicine’s Biosimilar SaiYueXin Seeks NMPA Approval for Crohn’s Disease

Fineline Cube Feb 13, 2025

Huadong Medicine Co., Ltd (SHE: 000963) announced that another indication approval filing for its SaiYueXin,...

Posts pagination

1 … 237 238 239 … 690

Recent updates

  • Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program
  • Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy
  • Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched
  • TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations
  • TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma – Novel Non-Covalent Approach Shows Enhanced Safety Profile
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Company Drug

TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.